Cenisertib (AS-703569) is a multi-kinase inhibitor and blocks the activity of Aurora-kinase-A/B, AKT, ABL1, STAT5, and FLT3. Cenisertib inhibits tumor growth in xenograft models of breast, pancreatic, ovarian, colon, lung tumors, and leukemia.

Cenisertib (1-1000 nM; for 48 hours) induces a dose-dependent inhibition of proliferation in primary neoplastic mast cells (MC). Cenisertib (1-1000 nM; for 24 hours) induces apoptosis in HMC-1.1, HMC-1.2, C2, and NI-1 cells in a dose-dependent manner. Cenisertib (5-500 nM; for 24 hours) induces cleavage of caspase 3 in both HMC-1 sub-clones as well as in C2 and NI-1 cells. Cenisertib (5-100 nM; for 24 hours) induces a substantial G2/M cell cycle arrest at low nanomolar concentrations in all MC lines [1].

Cenisertib (p.o.; 7 or 10 mg/kg/day; for 3 days) evidently suppresses tumor growth [2].

871357-89-0

C24H30FN7O

451.54

R-763;AS-703569

DMSO:250 mg/mL (553.66 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years